Table 1. Toxicity of ciprofloxacin derivatives in mice.
Compound dose (mg/kg) | Mouse weight (g) | Serum urea a | Serum creatinine kinase b | |
---|---|---|---|---|
Initial | After 48 h | |||
Vehicle | 20.15 | 21.28 | 53.0 | ND |
Et-Cipro 25 | 19.87 | 22.25 | 55.8 | 1727 |
50 | 19.15 | 20.92 | 51.2 | 182 |
100 | 20.71 | 22.27 | 55.1 | 578 |
200 | 20.0 | 22.17 | 49.3 | 583 |
Vehicle | 19.30 | 21.91 | 48.0 | 420 |
Adam-Cipro 25 | 20.65 | 23.10 | ND | ND |
50 | 20.80 | 22.12 | ND | ND |
100 | 20.45 | 23.50 | ND | ND |
200 | 21.11 | 23.28 | 51.5 | 467 |
Vehicle | 19.49 | 22.94 | 46.7 | 563 |
Ph-Cipro 25 | 21.21 | 23.85 | 49.2 | ND |
50 | 19.30 | 22.72 | 50.6 | 506 |
100 | 19.21 | 21.94 | 52.8 | ND |
200 | 19.93 | 22.20 | 46.2 | 1541 |
Swiss mice were administrated with a single oral dose of different ciprofloxacin derivatives, and monitored for 48h.
Serum levels of urea and creatinine kinase were measured in blood samples harvested 40h after drug administration. The following reference values (mg/kg) were used:
a18–29 mg/dL
b, ≤ 1070 U/L.